A Phase IV Open-Label, Single-Cohort Study of the LongTerm Neurocognitive Outcomes in 4 to 5 Year-Old Children with Phenylketonuria Treated with Sapropterin Dihydrochloride (Kuvan®) for 7 Years

Back to trials